FDA Clearance Tracker · P150026-S015
HeartLight Catheter, HeartLight X3 Console V2
Last checked: Nov 20, 2026Latest source record: Aug 11, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Aug 11, 2023
Approved
Time to decision
162 days
Received Mar 2, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P150026-S015
- Device name
- HeartLight Catheter, HeartLight X3 Console V2
- Applicant
- Cardiofocus, Inc.
- Applicant location
- Marlborough, MA
- Received
- Mar 2, 2023
- Decided
- Aug 11, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P150026
Device type
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the transition of the Console manufacturing from the current contractor, Minnetronix, 1635 Energy Park Dr, St Paul, MN 55108 USA to Gener8, 2560 Junction Ave., San Jose CA 95134 USA.
Source documents
Other decisions for Cardiofocus, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P150026 · Decided Apr 1, 2016 · 246 days after receipt
Device type: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation (OAE) · Cardiology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.